Leukemia risk following Hodgkin's disease : relation to cumulative dose of alkylating agents, treatment with teniposide combinations, number of episodes of chemotherapy, and bone marrow damage.
The development of leukemia is one of the most serious long-term complications of modern treatment for Hodgkin's disease (HD).
This study was undertaken to examine the relation between risk of leukemia and various treatment factors (including cumulative dose of cytostotic drugs and interaction with radiotherapy [RT]), while also assessing the effect of treatment-induced bone morrow damage.
Patients and Methods
We conducted a case-control study in a cohort of 1,939 patients treated for HD between 1966 and 1986 in the Netherlands.
Detailed information from the medical records was obtained for 44 cases of leukemia and 124 matched controls, in whom leukemia had not developed.
Mots-clés Pascal : Hodgkin maladie, Carcinogène, Toxicité, Leucémie, Facteur risque, Chlorméthine, Lomustine, Anticancéreux, Epidémiologie, Téniposide, Inhibiteur enzyme, DNA topoisomerase (ATP-hydrolysing), Isomerases, Enzyme, Chimiothérapie, Dose cumulée, Association médicamenteuse, Lésion, Moelle osseuse, Homme, Nitrosourées, Agent alkylant, Hémopathie maligne, Lymphoprolifératif syndrome, Lymphome, Traitement, Podophyllotoxine dérivé, Etude cas témoin
Mots-clés Pascal anglais : Hodgkin disease, Carcinogen, Toxicity, Leukemia, Risk factor, Antineoplastic agent, Epidemiology, Enzyme inhibitor, DNA topoisomerase (ATP-hydrolysing), Isomerases, Enzyme, Chemotherapy, Cumulated dose, Drug combination, Lesion, Bone marrow, Human, Nitrosoureas, Alkylating agent, Malignant hemopathy, Lymphoproliferative syndrome, Lymphoma, Treatment, Case control study
Notice produite par :
Inist-CNRS - Institut de l'Information Scientifique et Technique
Cote : 94-0529652
Code Inist : 002B02U10. Création : 199501.